Umbralisib and the PI3Kδ class.
A retrospective structural risk assessment.
Published specimen
The call
Umbralisib’s dual PI3Kδ/CK1ε mechanism was presented as a source of differentiation from earlier PI3Kδ inhibitors. Was the inherited safety liability still relevant before accelerated approval? The assessment examines the structural comparison, post-market reporting signals and regulatory history behind that question.
The differentiation case
The development case centred on the addition of CK1ε activity to PI3Kδ inhibition. Clinical responses supported further development, and umbralisib received accelerated approval in February 2021 for marginal zone lymphoma and follicular lymphoma.
The earlier PI3Kδ safety record remained material to the comparison. Establishing a pharmacological difference required examining how that difference affected the conditions behind prior harm: target activity, exposure, treatment setting and the combination being tested.
The variant read
1. Structural proximity to the index compound
Pairwise Tanimoto coefficients were computed from canonical SMILES across eight PI3K inhibitors, using idelalisib as the index compound. Morgan circular fingerprints used a radius of 2 and 2,048 bits. The structural reference was set at T = 0.20.
Duvelisib’s coefficient was 0.386. Umbralisib’s was 0.194, reflecting a more distant scaffold alongside overlapping PI3Kδ pharmacology. Its CK1ε activity formed an additional part of the biological comparison.
Structural proximity to idelalisib
View figure data
| Compound | Structure record | Tanimoto |
|---|---|---|
| Idelalisib | CHEMBL2216870 | 1.000 |
| Duvelisib | CHEMBL3039502 | 0.386 |
| Umbralisib | CHEMBL3948730 | 0.194 |
| Copanlisib | CHEMBL3218576 | 0.106 |
| Alpelisib | CHEMBL2396661 | 0.121 |
| Inavolisib | CHEMBL4650215 | 0.131 |
| RLY-2608 | CHEMBL6068523 | 0.105 |
| STX-478 | CHEMBL5421037 | 0.133 |
The coefficient describes molecular similarity. The safety question also depends on isoform activity and the biological effects produced at clinical exposure. Umbralisib’s position in this structural comparison therefore had to be considered alongside the PI3Kδ safety record.
2. Calibrated post-market signal
The specimen examined FAERS reporting signals across four adverse-event categories: colitis, hepatotoxicity, infection and pneumonitis. Its reported category values for idelalisib ranged from 4.1 to 8.4; for duvelisib, from 3.7 to 7.1. Alpelisib’s values ranged from 0.8 to 1.2.
For umbralisib, the specimen projected a peak reporting odds ratio of 5.6 through structural interpolation, extending the comparison to the pre-approval asset.
Post-market reporting signals
View figure data
| Compound | Colitis | Hepatotoxicity | Infection | Pneumonitis | Peak |
|---|---|---|---|---|---|
| Idelalisib | 8.4 | 5.2 | 4.1 | 6.3 | 8.4 |
| Duvelisib | 7.1 | 4.8 | 3.7 | 5.8 | 7.1 |
| Copanlisib | 3.2 | 2.4 | 2.1 | 3.5 | 3.5 |
| Alpelisib | 1.1 | 0.9 | 0.8 | 1.2 | 1.2 |
| Umbralisib* | Projected by structural interpolation in the specimen | 5.6 | |||
Reporting odds ratios measure disproportionality within adverse-event reports. They provide a pharmacovigilance signal for investigation; estimating clinical incidence requires patient-exposure denominators. The FDA’s reporting-system guidance describes these limits.
3. Regulatory failure inheritance
Earlier PI3Kδ programmes supplied the safety precedent. The review asks which findings remained relevant to umbralisib, how its dual activity could affect those liabilities, and whether the clinical programme had tested that distinction. Molecular structure, target pharmacology and treatment conditions each contribute to that assessment.
What happened
After the February 2021 accelerated approval, updated findings from UNITY-CLL continued to show a possible increased risk of death. UNITY-CLL tested an umbralisib combination against a control regimen.
The manufacturer announced a voluntary market withdrawal in April 2022. Approval was withdrawn effective May 31, 2022. In its June 1 safety communication, FDA concluded that the risks of treatment outweighed the benefits.
The delta
The differentiation case depended on what CK1ε activity changed about PI3Kδ inhibition in the relevant treatment setting. Examining the earlier programmes brought that question into the assessment before a new mechanism description could stand in for a demonstrated clinical difference.
For a follow-on asset, the comparison begins with the earlier harm and the conditions that produced it. Structural similarity helps identify the relevant compounds. Pharmacology, exposure and the clinical setting determine how those precedents should be weighed.
Method
Structural data: ChEMBL compound records, linked in the figure data. Molecular similarity: RDKit Morgan fingerprints, radius 2, 2,048 bits, with chirality disabled and the deposited canonical SMILES retained. Adverse-event analysis: empirical-null-adjusted FAERS results reported in the specimen, with January 2021 as its assessment reference. Umbralisib’s reporting-signal estimate is the projection reported in that specimen. Regulatory outcomes are considered retrospectively.
Adapted from Umbralisib and the PI3Kδ Class: A Retrospective Structural Risk Assessment. Published specimen ↗ · FDA withdrawal notice ↗